| INTRODUC TI ON
Coronary artery disease (CAD), mainly caused by atherosclerosis and plaque formation in coronary arteries, is the most common type of ischemic cardiovascular disorder, which has become the leading cause of global death along with its consequent complications including angina, heart failure, and myocardial infarction.
1 Drugeluting stents in CAD treatment are scaffolds placed in coronary artery that locally elute anti-proliferative and anti-inflammatory drugs to counteract vessel wall recoil and reduce restenosis after widening the coronary arteries with percutaneous coronary intervention (PCI). 2-5 Although PCI with drug-eluting stents implementation has improved clinical outcomes in CAD patients, the occurrence rate of restenosis remains high in CAD patients treated with drug-eluting stents, and complications particularly rapid angiographic stenotic progression (RASP) of the nontarget lesion are frequently reported to accompany PCI. 6 Therefore, it is of great need to explore potential markers for prediction of RASP and restenosis risks to improve quality of life for CAD patients underwent PCI with drug-eluting stents implementation.
Various clinical indexes including precipitating factors (eg, smoking and inflammation), biochemical parameters (eg, lipoprotein and cholesterol), coronary angiograms (eg, lesion size and number), or diseases history (eg, obesity, diabetes mellitus (DM), and hypertension) have been widely used for forecasting disease risk, monitoring disease severity, and predicting prognosis in CAD patients.
3,6-15
However, limited information is available about the function of these clinical indexes on the risk of RASP and restenosis in CAD patients after PCI with drug-eluting stents implantation. In the present study,
we collected comprehensive baseline, procedural, and postprocedure characteristics of patients and aimed to explore their correlation with the risk of RASP at the nontarget lesion and restenosis of target lesion in CAD patients after PCI with drug-eluting stents implantation.
| MATERIAL S AND ME THODS

| Patients
Two hundred fourteen CAD patients who underwent PCI with drug- 
| Ethics statement
This study was approved by the Institutional Review Board of The Second Hospital of Hebei Medical University and performed in accordance with the Declaration of Helsinki. Written informed consents were obtained from all patients before enrollment.
| Data collection
Baseline, procedural, and postprocedure characteristics of pa- 
| Coronary angiography
Coronary angiography was performed to evaluate coronary stenosis before PCI, immediately after PCI and at 12 months after PCI. The operation and projection position of two coronary angiographies were consistent to obtain comparable diagnostic angiograms.
Coronary angiogram was obtained with the use of Angiography System (Siemens, Germany), and quantitative coronary angiographic analysis of atherosclerotic plaques and luminal stenosis was performed using supporting software system according to the standard operating procedure. Before angiography, 0.5 mg glycerin trinitrate was given to the patient, and 5 minutes later the contrast agent was injected, then coronary angiogram was acquired. Coronary angiogram was analyzed and evaluated by two independent experienced specialists.
| PCI and drug-eluting stents implantation
In the present study, PCI, drug-eluting stents implantation, and 
| RE SULTS
| Study flow
Initially, a total of 457 CAD patients were invited, whereas 81 patients were excluded including 64 patients missed the invitation and 17 patients declined to attend prescreening procedure. 376 patients were then screened for eligibility, while 90 patients were excluded CAD, coronary artery disease; BMI, body mass index; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; FBG, fasting blood-glucose; Scr, serum creatinine; SUA, serum uric acid; cTnI, cardiac troponin I; NT-proBNP, N-terminal probrain natriuretic peptide; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell; LAD, left anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; ACEIs/ARBs, angiotensin converting enzymes inhibitors/angiotensin receptor blockers. Data were presented as mean value ± standard deviation, median (25th-75thquantiles), or count (percentage). RASP, rapid angiographic stenotic progression; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; FBG, fasting blood-glucose; Scr, serum creatinine; SUA, serum uric acid; cTnI, cardiac troponin I; NT-proBNP, N-terminal probrain natriuretic peptide; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell; LAD, left anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; ACEIs/ARBs, angiotensin converting enzymes inhibitors/angiotensin receptor blockers. Data were presented as P value, OR (odds ratio), and 95% CI (confidence interval). P value <0.05 was considered significant. Factors affecting RASP occurrence were determined by univariate logistic regression model analysis, and "-" indicated that there was no statistical performance due to lack of events. Statistically significant values were shown in bold font. 
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| Comparison of characteristics between RASP group and non-RASP group
A total of 81 (37.8%) CAD patients occurred RASP at 12 months after PCI, according to which patients were divided into RASP (N = 81) and non-RASP groups (N = 133), and we found that RASP group presented with increased DM complication (P = 0.035), higher concentrations of SUA (P = 0.006), cTnI (P = 0.022), NT-proBNP (P = 0.026), hs-CRP (P = 0.001), and raised occurrence of multivessel artery lesions (P = 0.001) as well as bifurcation requiring double wiring (P = 0.001) compared to non-RASP group, while no difference in other characteristics between the two groups was observed (Table 2) .
| Logistic regression analysis for factors affecting RASP occurrence in CAD patients
Univariate regression model analysis revealed that DM (P = 0.037), SUA (P = 0.008), hs-CRP (P < 0.001), multivessel artery lesions (P = 0.001), and bifurcation requiring double wiring (P = 0.001) were positively correlated with the risk of RASP (Table 3) . And multivariate logistic regression model analysis with the Forward Stepwise (Conditional) method further illustrated that DM (P = 0.022), SUA (P = 0.011), hs-CRP (P < 0.001), multivessel artery lesions (P = 0.010), and bifurcation requiring double wiring (P = 0.001) independently predicted higher risk of RASP (Table 4) .
| Comparison of characteristics between restenosis group and nonrestenosis group
Totally 45 (21.0%) patients occurred restenosis at 12 months after PCI, depending on which patients were divided into restenosis group (N = 45) and nonrestenosis group (N = 169), and in restenosis group, patients presented with increased hypertension (P = 0.017) and DM (P = 0.013) occurrence, higher concentrations of SUA (P = 0.020), LDL-C (P = 0.010) and hs-CRP (P < 0.001), longer length of target lesion (P = 0.029) and length of stent (P = 0.026) used in PCI surgery as well as higher rate of bifurcation requiring double wiring (P = 0.002), whereas no difference was found in other characteristics between the two groups (Table 5 ).
| Logistic regression analysis for factors affecting restenosis occurrence in CAD patients
Univariate regression model analysis revealed that hypertension (P = 0.022), DM (P = 0.015), SUA level (P = 0.021), LDL-C level (P = 0.011), hs-CRP level (P =< 0.001), length of target lesion (P = 0.032), length of stent used in PCI surgery (P = 0.031), and bifurcation requiring double wiring (P = 0.003) were risk factors for restenosis occurrence (Table 6 ).
In addition, multivariate logistic regression analysis with the Forward
Stepwise (conditional) method exhibited that DM (P < 0.001), SUA (P = 0.049), LDL-C (P < 0.001), hs-CRP (P < 0.001), length of target lesion (P = 0.002), and bifurcation requiring double wiring (P = 0.009) were independent factors for predicting increased occurrence of restenosis (Table 7) .
| D ISCUSS I ON
Our study discovered that in CAD patients underwent PCI with drug-eluting stents implantation: (a) 1-year occurrence of RASP was 37.8%, and DM, SUA, hs-CRP, multivessel artery lesions as well as bi- In CAD treatment, the adoption of PCI and drug-eluting stents presents great effect on unchoking the stenosis of coronary artery, preventing vessel wall recoil, and inhibiting neointimal growth of the targeted lesion, while the treatment efficacy has been frequently reported to be attenuated by occurrence of RASP and restenosis, which becomes one of the major clinical challenges for CAD treatment. 16 Although the exact mechanism of RASP in CAD patients is unclear, it is currently accepted that rupture of plaques and the subsequent injury response facilitate the accretion of the vascular wall and contribute to RASP. 17 Clinical studies disclose that CRP level is positively associated with RASP of nontarget lesion in angina patients after stents implantation.
12,13
Another study reports that elevation of CRP predicts rapid an- From literature, the incidences of restenosis are diverse in different studies. A study from Japan concludes that incidence of restenosis at ostial lesion of right coronary artery is 34% in 6-18 months.
20
In CAD patients complicated with DM, the incidence of restenosis is around 20% over 6 months after drug-eluting stent implantation.
3,21
Whereas in our study, different follow-up time (12 months), general CAD patients rather than CAD patients with specific complications were recruited, therefore, our study yielded different but reasonable incidence rate of restenosis being 21.0%. Restenosis is believed to be caused by arterial remodeling and neointimal hyperplasia, and plenty of studies have been performed investigating the factors associated with restenosis risk in CAD patients. 6 DM history has been exhibited to be correlated with higher incidence of restenosis in CAD patients after PCI. 22 And serum very low-density lipoprotein cholesterol (VLDL-C), SUA level, as well as history of PCI in CAD patients independently predict high restenosis risk. 3 Also, elevated hs-CRP level has been disclosed to promote the rate of restenosis in CAD patients after drug-eluting stents implantation. 19, 23 In line with these previ- There were still several limitations in our study. Firstly, RASP and restenosis were evaluated at 12 months after PCI; thus, the correlation of the candidate factors with the long-term RASP and restenosis risk in CAD patients underwent PCI with drug-eluting stents implantation was not investigated. Secondly, the number of patients recruited was relatively small, and large scale of predictive factors was included for analysis, which might reduce the BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; FBG, fasting blood-glucose; Scr, serum creatinine; SUA, seru-m uric acid; cTnI, cardiac troponin I; NT-proBNP, N-terminal probrain natriuretic peptide; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell; LAD, left anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; PCI, percutaneous coronary intervention; ACEIs/ARBs, angiotensin converting enzymes inhibitors/angiotensin receptor blockers. Data were presented as P value, OR (odds ratio), and 95% CI (confidence interval). P value <0.05 was considered significant. Statistically significant values were shown in bold font. Factors affecting restenosis occurrence were determined by univariate logistic regression model analysis, and "-" indicated that there was no statistical performance due to lack of events.
TA B L E 6 (Continued) DM, diabetes mellitus; SUA, serum uric acid; LDL-C, low-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein.
Data were presented as P value, OR (odds ratio), and 95% CI (confidence interval). P value <0.05 was considered significant. Factors affecting restenosis occurrence were determined by multivariate logistic regression model analysis with the Forward Stepwise (Conditional) method.
Statistically significant values were shown in bold font.
